Imagine needing a life-saving medication for Wilson’s disease. In the United Kingdom, that treatment costs $1,400 annually. In Germany, it’s $2,800. But if you live in the United States, you might be handed a bill for $88,800. That is not a typo. It is a stark reality documented by Senator Bernie Sanders in his September 2025 report on prescription drug pricing.
This isn’t just about one rare condition. Americans pay significantly more for medications than citizens of other developed nations, despite accessing the exact same pills from the same factories. The U.S. accounts for less than 5% of the global population yet generates approximately 75% of global pharmaceutical profits, according to a White House fact sheet from November 2025. Why does this disparity exist? The answer lies in a complex web of legislative bans, opaque middlemen, and market structures that prioritize profit over patient affordability.
The Legislative Ban on Price Negotiation
To understand why prices are so high, we have to look back two decades. The root cause traces directly to the Medicare Modernization Act of 2003, which prohibited Medicare from negotiating drug prices directly with manufacturers. For over twenty years, this law created a structural disadvantage. While other OECD countries use their purchasing power to negotiate lower rates, U.S. insurers were largely barred from doing the same for Medicare beneficiaries.
This ban meant pharmaceutical companies could set near-total pricing autonomy. Without the threat of government negotiation, there was little pressure to keep prices aligned with international standards. Recent efforts to change this have faced significant hurdles. The Inflation Reduction Act introduced provisions allowing Medicare to negotiate prices for certain drugs, but these measures took effect slowly. By 2026, only ten drugs were covered under this new negotiation program, projected to save $1.5 billion in annual out-of-pocket costs. However, the 2025 budget reconciliation bill (HR 1) weakened these provisions, increasing Medicare spending by at least $5 billion, according to KFF analysis.
The Role of Pharmacy Benefit Managers (PBMs)
If legislation set the stage, Pharmacy Benefit Managers (PBMs) are the actors complicating the script. Originally designed as third-party administrators to negotiate discounts on behalf of patients, PBMs have evolved into vertically integrated entities with massive market power. A Morgan Lewis analysis from April 2025 highlights how these intermediaries now influence final drug costs in ways that often hurt consumers.
Here is how it works: PBMs negotiate rebates with drug manufacturers. Often, these rebates are tied to higher list prices. Instead of lowering the cost for the patient, the system incentivizes manufacturers to raise prices so they can offer larger rebates to PBMs. This creates a cycle of opacity where the true cost of the drug is hidden behind layers of negotiations. The result? Patients see skyrocketing list prices, while PBMs capture a significant portion of the value. This lack of transparency has prompted HHS to announce forthcoming changes to prescription drug price transparency in September 2025, aiming to provide real-time price information to empower consumers.
| Country | Pricing Mechanism | Government Negotiation | Average Patient Cost (Relative) |
|---|---|---|---|
| United States | Market-driven, PBM rebates | Limited (Medicare only for select drugs) | Highest among OECD nations |
| Germany | Reference pricing | Direct negotiation | Low |
| France | Price caps & reference pricing | Direct negotiation | Low |
| Canada | Patented Medicine Price Review Board | Provincial negotiation | Low |
Specialty Drugs Driving Costs Up
Not all drugs contribute equally to rising costs. Specialty drugs-those used for cancer, endocrine conditions, and rare diseases-are the primary drivers of spending growth. IQVIA Institute reports that novel obesity and diabetes medications, such as Ozempic and Wegovy, have been significant contributors to the 11.4% growth in U.S. net drug prices in 2024. These drugs expand into new patient populations, creating unprecedented demand.
For example, before recent executive actions, monthly costs for Ozempic hovered around $1,000, and Wegovy around $1,350. In September 2025, the White House announced deals with manufacturers to reduce these prices to $350 per month. While this is a step forward, it highlights how high initial pricing remains the norm. Specialty drugs continue to drive expenditures, with projections showing overall prescription drug spending will rise by 9.0-11.0% in 2025. Clinics face even steeper increases of 11.0-13.0%, squeezing providers who serve vulnerable populations.
Political Promises vs. Market Reality
Despite bipartisan rhetoric about lowering drug costs, the market reality tells a different story. President Trump stated in September 2025 that Americans were "subsidizing socialism abroad" with high prices. Yet, Senator Sanders’ report revealed that 688 prescription drugs increased in price since he took office. Even after sending letters to manufacturers demanding price cuts, 87 drugs saw median price increases of 8%.
This contradiction stems from the complexity of the supply chain. Executive orders can direct agencies to develop recommendations, but they cannot easily override entrenched industry practices. The Prescription Drug Price Relief Act, introduced by Sanders in May 2025, proposes an international reference pricing system. This would cap U.S. prices at levels seen in other major countries. However, implementing such a system requires overcoming legal barriers, lobbying efforts, and the inertia of a multi-layered supply chain.
Impact on Patients and Future Outlook
The human cost of these policies is severe. CMS Administrator Chiquita Brooks-LaSure noted that the Inflation Reduction Act’s $2,000 annual out-of-pocket cap for Medicare will be "life-changing" for many. Conversely, the Center for American Progress warns that Project 2025’s prescription drug plan could increase costs for up to 18.5 million seniors. Medication rationing becomes a grim reality when patients must choose between buying insulin or paying rent.
Looking ahead, the landscape remains volatile. The Medicare drug price negotiation program expands in 2026, but its impact is limited. National security concerns are also emerging, with Johns Hopkins analysis highlighting pharmaceutical supply chains as strategic assets. As tariffs and trade policies evolve, drug pricing may become even more entangled in geopolitical debates.
For now, the fundamental structural issues enabling high drug prices remain largely unaddressed. Until comprehensive reform tackles the roles of PBMs, strengthens government negotiation powers, and aligns U.S. prices with international standards, patients will continue to bear the burden of a broken system.
Why do drug prices increase faster in the U.S. than in other countries?
The U.S. lacks direct government price negotiation for most drugs due to the Medicare Modernization Act of 2003. Additionally, Pharmacy Benefit Managers (PBMs) create a complex rebate system that incentivizes higher list prices rather than lower consumer costs. Other countries use reference pricing or direct negotiation to control costs.
What is the role of PBMs in drug pricing?
PBMs act as intermediaries between insurers, pharmacies, and drug manufacturers. They negotiate rebates, but these rebates are often tied to higher list prices. This structure allows PBMs to capture significant value while leaving patients with high out-of-pocket costs.
How does the Inflation Reduction Act affect drug prices?
The Inflation Reduction Act allows Medicare to negotiate prices for certain high-cost drugs and imposes rebates on manufacturers who raise prices faster than inflation. It also sets a $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries, though its full impact is being rolled out gradually.
Are specialty drugs responsible for most price increases?
Yes, specialty drugs for cancer, endocrine conditions, and rare diseases drive disproportionate spending growth. Novel treatments for obesity and diabetes, such as Ozempic and Wegovy, have also contributed significantly to recent price escalations.
What is international reference pricing?
International reference pricing is a policy that caps U.S. drug prices at levels comparable to those in other developed nations. Proposed in the Prescription Drug Price Relief Act, it aims to eliminate the markup Americans pay for the same medications available elsewhere.